AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04511520
Drug: Trimetazidine
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01169675
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: given intravenously on day 1 of a 21 day cycle
Trial: NCT01169675
Drug: BIBW 2992 high dose 6 day
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
Trial: NCT00510536
Drug: NSAID
RxNorm normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose to be determined by investigator
Trial: NCT00624936
Drug: Vidaza
RxNorm normalized name: Vidaza
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.
Trial: NCT00624936
Drug: Velcade
RxNorm normalized name: Velcade
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
Trial: NCT03061136
Drug: Clonazepam
RxNorm normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04404764
Drug: Nusinersen Injectable Product
RxNorm normalized name: nusinersen Injectable Product
DrugBank: Nusinersen (DB13161)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patient´s treatment is provided by SUS. The following dosage scheme of nurinersen is the one approved by ANVISA (Brazilian National Health Surveillance Agency): Nusinersen, 12 mg (5 mL) on days 0 (zero), 14 and 28. A fourth dose will be on day 63 with a maintenance dose once every 4 (four) months. The study will NOT have direct influence on the care received by patients. Data on adherence, interventions, hospitalizations, mechanical ventilation, procedures and adverse events will be obtained from the patients´ medical records.
Trial: NCT00912743
Drug: olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg po bid continuously
Trial: NCT01169675
Drug: BIBW 2992 low dose 6 day
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
Trial: NCT00060242
Drug: fosbretabulin disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses beyond documentation of the CR.
Trial: NCT02815332
Drug: BPX-01 Vehicle Topical Gel
RxNorm normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML [Penmenvy]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 1 gram applied once daily for 12 weeks
Trial: NCT01169675
Drug: BIBW 2992 medium dose 6 day
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
Trial: NCT01169675
Drug: BIBW 2992 medium dose
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
Trial: NCT00033358
Drug: medroxyprogesterone
RxNorm normalized name: Medroxyprogesterone
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intramuscularly
Trial: NCT00033358
Drug: ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00033358
Drug: norgestrel
RxNorm normalized name: Norgestrel
DrugBank: Norgestrel (DB09389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02682693
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab 120 mg every 4 weeks for 6 cycles
Trial: NCT02682693
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)
Trial: NCT02682693
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times
Trial: NCT02682693
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel
Trial: NCT02682693
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles
Trial: NCT02682693
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
Trial: NCT03259464
Drug: BI 685509
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 sequential dose groups
Trial: NCT01834742
Drug: Moviprep
RxNorm normalized name: MoviPrep
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.
Trial: NCT00936442
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
Trial: NCT01942681
Drug: Propiverine Hydrochloride
RxNorm normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrate Propiverine Hydrochloride for 12 weeks
Trial: NCT03829124
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 10mg/ml IV push slowly 0.5-2mg/kg
Trial: NCT03829124
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine 50mg/ml IV push slowly 0.5- 1mg/kg
Trial: NCT00445679
Drug: DVS SR
RxNorm normalized name: rAAVrh74.MHCK7.DYSF.DV
DrugBank: SRP-6004 (DB16998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
Trial: NCT00445679
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
Trial: NCT00066482
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children \< 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)
Trial: NCT00066482
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children \< 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)
Trial: NCT00637286
Drug: Zolmitriptan
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg Nasal Spray
Trial: NCT01602367
Drug: BMS-823778
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 2 mg, Once daily, 12 weeks
Trial: NCT01602367
Drug: BMS-823778
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 6 mg, Once daily, 12 weeks
Trial: NCT01602367
Drug: BMS-823778
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 15 mg, Once daily, 12 weeks
Trial: NCT01620190
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
RxNorm normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02239380
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to \< 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study.
Trial: NCT02608216
Drug: ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: therapeutic
Trial: NCT02608216
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: therapeutic
Trial: NCT03346135
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Undergo standard of care ASCT with a conditioning regimen of melphalan
Trial: NCT06461936
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receives first adjuvant PD-1monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
Trial: NCT06461936
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib is initiated orally 2-4 weeks postoperatively for about 6 months.
Trial: NCT03777436
Drug: Apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT00885664
Drug: Truvada (tenofovir/emtricitabine)
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir/emtricitabine fixed dose combination once daily
Trial: NCT00885664
Drug: Kaletra (lopinavir/ritonavir)
RxNorm normalized name: lopinavir / ritonavir Oral Tablet [Kaletra]
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lopinavir/ritonavir 400/100 mg twice daily
Trial: NCT00676364
Drug: 4% lidocaine topical anesthetic cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture
Trial: NCT00903708
Drug: LY2275796
RxNorm normalized name: LY2275796
DrugBank: LY2275796 (DB05165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
Trial: NCT02782559
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02080780
Drug: 2% Diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% Diltiazem Hydrochloride Cream applied on Day 1 \& Day 8 to the perianal area (\~2.5 cm \[1 inch\]; \~8.5 mg)
Trial: NCT00760045
Drug: Hydroxypropyl Guar Galactomannan
RxNorm normalized name: hydroxypropyl guar hydroxypropyltrimonium chloride
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
Trial: NCT03028909
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care for influenza caused by Type A strains
Trial: NCT01311076
Drug: TAK-329
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-329 50 mg, tablets, orally, single dose, one day.
Trial: NCT01311076
Drug: TAK-329
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-329 200 mg, tablets, orally, single dose, one day.
Trial: NCT01311076
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin 0.2 U/kg, subcutaneous injection, single dose, one day.
Trial: NCT00760045
Drug: 0.1% sodium hyaluronate ophthalmic solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
Trial: NCT00704600
Drug: nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I:~* take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 0: PET-CT~Phase II:~* take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 7 biopsy~* day 7, 21 and week 15 :PET-CT + perfusion CT
Trial: NCT00644917
Drug: Xenaderm
RxNorm normalized name: Xenaderm
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg under Finn chambers
Trial: NCT00758485
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
Trial: NCT00758485
Drug: 0.9% sodium chloride (NaCl)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
Trial: NCT00005580
Drug: bryostatin 1
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005580
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00232362
Drug: Pioglitazone (Actos)
RxNorm normalized name: pioglitazone Oral Tablet [Actos]
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00232362
Drug: Anti-diabetic agent other than pioglitazone or rosiglitazone
RxNorm normalized name: INVESTIGATIONAL ANTI-DIABETIC DRUGS
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00627965
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg tds
Trial: NCT00004063
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004063
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02299232
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: dexmedetomidine 100 mcg/mL was applied in 3 mcg/kg and 4 mcg/kg doses in 1 mL preperates, 0.5 mL for each nostril
Trial: NCT04054115
Drug: Alprostadil 5 MCG Injection
RxNorm normalized name: alprostadil 5 MCG Injection
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the MRI, Alprostadil infusion will be started and titrated to the target dose, ensuring there is a less than 20% drop in blood pressure from baseline. Repeat pressure and MRI flow measurements once Alprostadil reaches 0.1mcg/kg/min.
Trial: NCT01488383
Drug: Purified extract of Rebaudina Stevia-Stevioside
DrugBank: Stevioside (DB16882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
Trial: NCT01488383
Drug: Sodium saccharin
RxNorm normalized name: SODIUM SACCHARIN
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
Trial: NCT03001635
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.
Trial: NCT02589626
Drug: empagliflozin 10mg
RxNorm normalized name: EMPAGLIFLOZIN 10MG TAB
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02589626
Drug: empagliflozin 25 mg
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00762268
Drug: SAMe
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period.
Trial: NCT02308891
Drug: lactated Ringer's solution (vigorous hydration arm)
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~* Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~* At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour
Trial: NCT02308891
Drug: lactated Ringer's solution (standard hydration arm)
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP.
Trial: NCT05177276
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05177276
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00044629
Drug: zolpidem tartrate (Ambien)
RxNorm normalized name: zolpidem tartrate Oral Tablet [Ambien]
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00611572
Drug: iomazenil
RxNorm normalized name: Iomazenil
DrugBank: Iomazenil (DB14971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as IV infusion
Trial: NCT00611572
Drug: iomazenil
RxNorm normalized name: Iomazenil
DrugBank: Iomazenil (DB14971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline IV infusion
Trial: NCT04404517
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal antibody used in IBD treatment
Trial: NCT04690231
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apatinib orally daily and ifosfamide 1.8mg/m2/d d1-3, etoposide 100mg/m2/d d1-3
Trial: NCT04690231
Drug: ifosfamide and etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ifosfamide and etoposide
Trial: NCT00351702
Drug: Isoniazid with Ethambutol
RxNorm normalized name: ethambutol / isoniazid
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
Trial: NCT00582608
Drug: 131I-8H9
RxNorm normalized name: iobenguane (131I)
DrugBank: Iobenguane (DB06704)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m\^2 dose \[intended specific activity of \~20 mCi/mg protein\]